UPDATE | May 26, 2022

Samsung Biologics Bispecific Antibody Platform - A novel asymmetrical structure for therapeutic antibodies

  • MAIL

Bispecific%20Antibody%20Platform%20-%20A%20novel%20asymmetrical%20structure%20for%20therapeutic%20antibodies_Image.png
 

Herein, we introduce a Samsung Biologics proprietary bispecific antibody platform (SBL9), which enables strongly orthogonal pairing of heavy and light chains to ensure the desired formation of multiple chains.

Bispecific%20Antibody%20Platform%20-%20A%20novel%20asymmetrical%20structure%20for%20therapeutic%20antibodies_Image.png 

Herein, we introduce a Samsung Biologics proprietary bispecific antibody platform (SBL9), which enables strongly orthogonal pairing of heavy and light chains to ensure the desired formation of multiple chains.

  • CDO
  • CGMP
  • ADC
  • Bio Campus
  • IR
  • CMO

Share article

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required